About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Treating Clostridium difficile infections: Should fecal microbiota transplantation be reclassified from investigational drug to human tissue?

Fecal microbiota transplantation (FMT)has emerged as a highly effective treatment for Clostridium difficile infection(CDI), the most frequent cause of hospital-acquired infectious diarrhea indeveloped countries and the cause of nearly 30,000 annual deaths in the US. FMTis proving to be more effective at treating CDI than traditional antibacterialtherapy, and reduces the exposure of valuable antibiotics to potentialresistance. A systematic review to assess the efficacy of FMT for CDI treatmentshowed that across all studies for recurrent CDI, symptom resolution wasobserved in 85% of patients. The United States Food and Drug Administrationcurrently classifies FMT as an investigational drug, which imparts overlyrestrictive regulations that are impossible to apply to FMT in the same manneras conventional drugs. Reclassification of FMT to a human cell, tissue, andcellular and tissue-based product could potentially expand access to thisimportant treatment while maintaining rigorous safety standards.

Keywords: Clostridium; Difficile; FMT